Aeris Environmental Ltd Overview
Aeris Environmental is a Sydney-based micro-cap with two lines of business. The first is a specialty environmental chemicals business: HVAC&R coil hygiene, corrosion protection coatings, mould remediation and disinfectants. The second is AerisTech, a 60%-owned IoT building-intelligence subsidiary whose patented Syncromesh wireless mesh platform connects lighting, HVAC and sensors to a cloud analytics layer without re-cabling. After a pandemic-era spike in disinfectant sales (FY2020 revenue A$14.6M), revenue has settled around A$3M a year since FY2022. The company now positions itself as an integrated "chemistry plus data" provider for energy efficiency, asset protection and indoor environmental quality. Its growth vectors are the Syncromesh Omni wholesale kit, enterprise deployments of Syncromesh Prime (including an Australian bank), corrosion-protection OEM orders in the Middle East and US, and brewery hygiene in China, including Budweiser APAC. The investment case is constrained by a weak balance sheet. At 30 June 2026 the company had net liabilities of A$9.2M and A$12.3M of related-party borrowings classified as current, and its accounts carry an explicit going-concern material-uncertainty note [AR26].
The company's own description [AR26, Directors' Report – Principal Activities]. Aeris describes three principal activities:
-
research, development and commercialisation of proprietary technologies, and global distribution of HVAC/R hygiene, anti-corrosion and disinfectant products;
-
HVAC/R hygiene and remediation, indoor air quality and corrosion protection services;
-
development and commercialisation of the AerisTech Syncromesh ecosystem, a wireless IoT platform and cloud software for monitoring and managing smart-building asset performance.
The Directors state there was no significant change in the nature of activities in FY2026.
Independent characterisation. Aeris is effectively two businesses sharing one listed balance sheet.
Specialty chemicals: This is the established revenue base. It consists of formulated products made by contract manufacturers in Australia and, from FY2026, partly in China. The products are sold through wholesalers, OEMs, HVAC contractors and directly to enterprises. Its margin profile is typical of a specialty chemicals business: the company states a gross margin of 51–53%. Demand has historically been lumpy. It is driven by weather events (North Queensland mould remediation in FY2025), pandemic hygiene spending (FY2020–21) and single large orders, such as a ~A$308k repeat order from a UAE OEM in the June 2026 quarter [AR26].
AerisTech / Syncromesh: This is an early-commercial building-IoT platform. The hardware is a mesh of wireless nodes and gateways. The software is a cloud dashboard and analytics layer. The business model mixes upfront capital (hardware and installation) with recurring cloud and application revenue. Management describes add-on applications as generating high-margin, recurring, cloud-based revenue once the network is installed [AR26].
Revenue model mix (FY2026) [AR26 Note 5]:
The FY2026 mix shifted sharply from services to products. Services revenue fell 75%, from A$1.21M to A$0.30M, as weather-driven mould remediation in North Queensland normalised. Product sales rose 47% [AR26]. Subscription and licensing revenue is not separately disclosed. Syncromesh recurring cloud revenue is presumably embedded within sales and services, but it is not quantified.
Value-chain position. Aeris is an IP-owning formulator and brand owner, not a commodity chemical producer. It outsources most manufacturing and relies on distribution partners: electrical wholesalers, HVAC wholesalers, a US channel partner (H4 Enterprises), a UK distributor and integrator, and Amazon in the US (per a third-party summary of the July 2026 quarterly [AGG]). Related-party entities supply R&D (Novapharm Research), corporate services and distribution (Regional Corporate Services), and some product (Enviroguard Technologies) [AR26].
Customer types and end-markets. Customers include HVAC&R contractors and OEMs; commercial property owners and facility managers; financial institutions, including a leading Australian bank rolling out Syncromesh Prime; government infrastructure owners; aged care and health (Queensland Health became a direct supplier relationship in 2024 [AGG]); sporting and entertainment venues (Luna Park Melbourne [Q-Jan26]); breweries in China (Budweiser APAC, Beijing Yanjing Brewery); coil manufacturers (a US coil maker after year-end); and residential and flood-remediation customers.
Customer concentration. One customer accounted for about 37% of FY2026 external revenue, up from 6% in FY2025, through the Australian segment [AR26 Note 4]. The customer is not named.
Strategy
Stated strategy themes (paraphrased from AR26):
-
Focus where technology is differentiated. Concentrate on markets with a credible route to commercial scale: corrosion protection, mould remediation and hygiene in chemicals, with growing focus on China, the Middle East and the US; and building intelligence via Syncromesh.
-
Two routes to market for AerisTech. Pursue large enterprise deployments directly and through integrators (Prime), and use the electrical wholesale channel for scalable volume (Omni). The wholesale model is meant to grow the pipeline without a matching increase in direct sales and delivery resources.
-
Chemistry plus data. Position specialty chemicals to work with IoT data so customers can improve efficiency and environmental outcomes, and cross-sell both lines.
-
Recurring revenue. Use the installed Syncromesh network as a base for high-margin cloud applications, and build repeat order books in corrosion protection.
-
Financial discipline. Maintain gross margin, control expenditure and working capital, and expand the capital base "at the appropriate time".
ESG commitments. No formal emissions targets are disclosed. The product proposition relies on customers' regulatory drivers: NABERS, Scope 2 reporting and IFRS S1/S2 (AASB S2) climate disclosure in Australia; and China's chemical-safety and food-safety rules.
Cost programmes. No formal programme with numeric targets has been disclosed.
Medium-term financial targets. None published. The Likely Developments section of AR26 withholds forward guidance, citing unreasonable prejudice. The going-concern note refers to an internal sales budget expecting "material growth" from new product introductions. The CEO's incentive hurdle (EBITDA of at least 10% of sales; VWAP of at least A$0.50) gives an implicit aspiration, not guidance.
Products & Services
Pricing is not publicly disclosed for any product unless stated. Launch years are given only where documented.
5A. AerisTech — Building Intelligence
| Product | Description & capabilities | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Syncromesh (core platform) | Proprietary, patented wireless mesh of nodes and gateways that links lighting, HVAC and other building systems to a cloud platform without re-cabling. Automates lighting and climate, tracks energy by zone, and monitors occupancy and environmental conditions in real time. Interoperates with existing building management systems and third-party IoT/power-monitoring OEM devices [AR26; AR25] | Commercial and industrial buildings, new build and retrofit | Technology originated with Cognian; brought into AerisTech in Sep 2024 | Hardware and installation (capital) plus recurring cloud/application revenue [AR26] |
| Syncromesh Prime | Project-engineered version for larger or complex sites, where an integrator designs the network to specification. Deployed at commercial, aged care, sporting facilities, a complex lighting-control site (Luna Park Melbourne) and a leading Australian bank [AR26; Q-Jan26] | Enterprises, government infrastructure, integrators | Commercial since FY2025; scaling in FY2026 | Project pricing; not disclosed |
| Syncromesh Omni | Standard pre-configured kit that an electrician can select, order and install without bespoke design. Aimed at smaller and retrofit commercial premises through electrical wholesale channels [AR26] | Electricians and electrical wholesalers; SME commercial premises | Commercial launch targeted for Q1 FY2027 (Jul–Sep 2026) [Q-Apr26]; AR26 says it is now listed with major wholesalers and generating growing orders | Wholesale kit pricing; not disclosed |
| Thermal occupancy sensing | Camera-free people counting and dwell-time measurement, described as privacy-assured and free of the issues of AI camera installs [AR26] | Banks, retail, offices | Part of Prime deployments | Bundled |
| Cloud dashboard / analytics | Bespoke cloud dashboard providing actionable energy and occupancy data; supports NABERS, Scope 2 and IFRS S1/S2 reporting needs [AR26; Q-Apr26] | Facility managers and ESG reporting teams | Live | Recurring; not disclosed |
5B. Specialty Chemicals — Corrosion Protection
| Product | Description | Target customer | Notes |
|---|---|---|---|
| Corrosion protection coatings for HVAC coils (Aeris Coil Protect range) | Thin specialty coatings for air-conditioning heat exchangers that do not impair heat-exchange performance. Independently tested to the ASTM B117 salt-spray standard; still passing after more than five years of continuous exposure [AR26] | HVAC&R contractors, OEMs, owners of coastal, marine, offshore, humid industrial and food-plant assets | Principal FY2026 growth area; repeat orders from a UAE OEM; customers in Saudi Arabia, Qatar and Australia; first US coil-manufacturer order after year-end |
5C. Specialty Chemicals — HVAC&R Hygiene, Mould & Environmental Hygiene
| Product | Description | Target customer | Notes |
|---|---|---|---|
| AerisGuard multi-enzyme coil/HVAC hygiene range | Patented multi-enzyme antimicrobial cleaners that remove contaminants and protect against recontamination, with protection claims of up to 12 months [AGG – Small Caps] | HVAC contractors, facility managers | Long-standing core range |
| Indoor Coil Treatment (aerosol 200g, AG-CT-A; 5L, AG-CT-5) | Ready-to-use coil treatment; validated coil efficiency improvement; 12-month protection claim [product sheet, aeris.com.au] | HVAC servicing | Current |
| Aeris Guard Bioactive Filter Treatment | Biodegradable active biocide for filters, claimed to kill 99.99% of bacteria and enveloped viruses [AGG – trade press] | HVAC filters | Pandemic-era addition |
| Mould prevention / Mould Stop Paint | Mould-control coating and remediation chemistry; Mould Stop Paint referenced in the March 2026 quarter [Q-Apr26] | Residential, aged care, flood/mould remediation | Current |
| Enzyme-based cleaning chemistry and anti-biofilm formulations (China) | Formulations against biofilm and microbial fouling that protect heat-exchange assets in breweries [AR26] | Brewers (Budweiser APAC, Yanjing) | Locally manufactured in China from FY2026 |
| Seal repair and hygiene automation solutions | Part of the Budweiser APAC opportunity set [AR26] | Brewers | Early stage |
5D. Specialty Chemicals — Surface Disinfection
| Product | Description | Notes |
|---|---|---|
| Aeris Active | Dual-active biocide hospital-grade disinfectant listed on the ARTG. Residual claims of up to seven days against COVID-19 and up to 30 days (200 touches) antibacterial; on Singapore NEA's interim COVID-19 list [AGG – trade press, 2020] | Main driver of FY2020 revenue |
| Aeris Defence (750mL trigger AG-AD-750; 5L AG-AD-5) | TGA-approved, Australian-made broad-spectrum disinfectant cleaner. Kills COVID-19, influenza and bacteria in a single step, with 24-hour ongoing disinfection after a single application [product sheet; Australian Made] | Current range |
| Hard-surface disinfecting paper | Biodegradable, renewably sourced disinfecting wipes/paper [AGG – trade press] | Pandemic-era line |
5E. Services
| Service | Description | FY2026 revenue |
|---|---|---|
| HVAC/R hygiene and remediation; IEQ / indoor air quality services; flood and mould remediation; corrosion protection services | Over-time service contracts, concentrated in North Queensland remediation in FY2025 | A$297,895 (FY2025: A$1,212,441) [AR26] |
Financial Narrative
Income statement
Notes:
-
TipRanks shows FY2024 gross profit as -A$0.18M, which is inconsistent with the company's stated margins and probably reflects an inventory write-down classification. It is excluded as unverifiable.
-
The company states gross margin as 51% (FY2025) and 53% (FY2026) [AR26]. Gross profit computed from statutory sales less cost of sales gives 47.5% and 51.2% respectively. The difference likely reflects management's definition, for example a quarterly or product-only basis.
Margins (%) — derived
Revenue CAGR: FY2022–FY2026 ≈ +3.5% a year (derived). FY2021–FY2026 ≈ -15.5% a year (from A$7.13M). FY2020–FY2026 ≈ -22.9% a year (from A$14.63M).
Half-year and quarterly revenue: notes and sources
Sources: AR26 for Q1 and Q4; Q2 derived from HY26 H1 revenue of A$1,077,773; [Q-Jan26], [Q-Apr26], [Q-Jul26].
Balance sheet
Notes:
-
FY2023 figures (cash, total assets, current liabilities of A$1.67M) and FY2024 cash and long-term debt are from InvestSMART/Morningstar [AGG].
-
FY2024 equity is the opening balance at 1 July 2024 from the AR26 statement of changes in equity.
-
Inventory is carried net of a A$2.48M impairment provision against gross inventory of A$3.25M [AR26 Note 10]. This is a large legacy write-down, most likely of pandemic-era disinfectant stock.
Borrowings detail [AR26]:
-
Loans from Directors and a shareholder total A$11,152,904 at a fixed 10%. They include capitalised interest; AR26 reports facilities of A$10.17M plus A$0.98M capitalised interest.
-
Loans from JV partner Cognian total A$1,191,000 and are non-interest-bearing.
-
Director loan balances at year-end: Maurie Stang A$4,544,383; Steven Kritzler A$2,231,845. The balance is attributable to substantial shareholder Bernard Stang (by inference from the AGM resolution).
-
All borrowings were reclassified from non-current to current under their repayment terms.
Cash flow
FY2022–FY2024 operating cash flow is from Stoxray/InvestSMART [AGG].
Ratios — derived
ROE, ROIC and debt/equity are not meaningful (n/m) because equity is negative and EBITDA is negative.
Commentary
Revenue. The revenue history has three phases. First, a pandemic boom: FY2020 revenue of A$14.6M and a profit of about A$2.0M, driven by the ARTG-listed Aeris Active disinfectant. Second, a sharp normalisation: A$7.1M in FY2021, then A$2.7M in FY2022 and A$1.9M in FY2023, with large losses and inventory write-downs. Third, a stabilisation at A$3.0–3.3M a year in FY2024–FY2026. FY2026 revenue fell 5.5% to A$3.08M. This masks a sharp change in mix and timing. The December 2025 quarter was very weak (about A$0.38M), while the June 2026 quarter was the strongest in at least two years (A$1.27M), driven by corrosion orders from the UAE OEM and Budweiser APAC. H2 FY2026 revenue of A$2.0M was up 13% on H2 FY2025 (derived). This is the most constructive data point in the filings.
Margins. Gross margin improved to a company-stated 53% from 51%, helped by the shift to product sales and the planned move of some manufacturing to China. The operating cost base of A$7.2M is about 2.3 times revenue, so breakeven at current gross margins would require revenue of roughly A$13–14M (derived). Administration costs rose 18% (corporate overheads up 25%), and finance costs rose 166% as related-party debt compounded at 10%.
Balance sheet. The balance sheet has deteriorated sharply. Shareholders' equity fell from roughly nil at 1 July 2024 to -A$9.2M at 30 June 2026. Accumulated losses reached A$73.1M against issued capital of A$62.5M. Borrowings have funded operations instead of equity since FY2025; there was no meaningful equity issue in either year. The current ratio collapsed to 0.36 because the A$12.3M of loans became current. The Directors intend to negotiate an extension, and say that if the loans were extended, current assets would exceed current liabilities by A$3.07M [AR26].
Working capital. The cash conversion cycle widened as trade receivables doubled. A A$324,630 fully-provided receivable was written off. Receivables older than 90 days were A$341k at year-end with no provision, which is worth monitoring [AR26 Note 9].
Going concern. AR26 Note 1 discloses a material uncertainty about the group's ability to continue as a going concern. It states the group remains dependent on capital raisings and that funding options, including a 2026 capital raise, have been investigated.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Entity / Unit Details
| Entity / unit | Ownership | Function |
|---|---|---|
Aeris Environmental Ltd | Listed parent | Head entity of the Australian tax-consolidated group; specialty chemicals |
AerisTech Pty Ltd | 60% Aeris / 40% Cognian Technologies Limited | Syncromesh building-intelligence platform (Prime and Omni) |
US subsidiary | Wholly owned (implied by US tax losses of A$5.39M) | Legacy US operations; corrosion and coil sales |
UK subsidiary | Wholly owned (UK tax losses) | UK distribution and Syncromesh |
China subsidiary | Wholly owned (China tax losses) | Aeris China team; local manufacturing capability |
Revenue by Segment
| Segment (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia – revenue from external customers | 2.949 | 2.750 |
International – revenue from external customers | 0.082 | 0.220 |
Total sales revenue (contracts with customers) | 3.030 | 2.970 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment — Australia – segment sales
| Segment (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia – segment sales | 3.133 | 3.075 |
International – segment sales | 0.082 | 0.220 |
Intersegment eliminations | -0.184 | -0.325 |
Segment pre-tax profit/(loss) (AUD Mn)
| Segment pre-tax profit/(loss) (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia | -4.339 | -5.592 |
International | -0.562 | -0.239 |
Eliminations | 0.317 | 0.245 |
Consolidated loss before tax | -4.584 | -5.587 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Australia external revenue YoY growth (%) | — | -6.7 |
International external revenue YoY growth (%) | — | 168.7 |
Australia share of external sales (%) | 97.3 | 92.6 |
International share of external sales (%) | 2.7 | 7.4 |
Australia PBT / segment sales (%) | -138.5 | -181.9 |
International PBT / segment sales (%) | -687.5 | -108.6 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 2.678 | 1.930 | 3.046 | 3.261 | 3.080 |
Revenue from contracts with customers (AUD Mn) | — | — | — | 3.030 | 2.970 |
Gross profit on sales (AUD Mn, derived) | 1.21 | 0.947 | — | 1.439 | 1.521 |
Operating income / EBIT (AUD Mn, derived for FY25–26) | -7.33 | -3.98 | -2.98 | -4.309 | -4.806 |
EBITDA (AUD Mn, derived for FY25–26) | -7.31 | -3.86 | -2.98 | -4.227 | -4.729 |
Finance costs (AUD Mn) | — | — | — | 0.299 | 0.796 |
Pre-tax income (AUD Mn) | -7.42 | -4.03 | -3.10 | -4.584 | -5.587 |
Income tax benefit, mainly R&D offset (AUD Mn) | — | — | — | 0.462 | 0.419 |
Net income, total (AUD Mn) | -7.13 | -3.65 | -2.97 | -4.122 | -5.167 |
Net income attributable to owners (AUD Mn) | -7.130 | -3.654 | -2.973 | -3.869 | -4.764 |
EPS basic (A$ cents) | -2.92 | -1.49 | -1.21 | -1.57 | -1.93 |
EPS diluted (A$ cents) | -2.92 | -1.49 | -1.21 | -1.57 | -1.93 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin on sales (%) | 45.2 | 49.1 | — | 47.5 | 51.2 |
Gross margin, company-stated (%) | — | — | — | 51 | 53 |
Operating margin (%) | -273.7 | -206.2 | -97.8 | -132.2 | -156.0 |
EBITDA margin (%) | -272.9 | -200.0 | -97.8 | -129.6 | -153.5 |
Net margin, total loss (%) | -266.2 | -189.1 | -97.5 | -126.4 | -167.7 |
Expense line (AUD Mn)
| Expense line (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Cost of sales | 1.592 | 1.449 |
Employee benefits | 1.825 | 1.778 |
Administration (total) | 2.512 | 2.966 |
of which compliance cost | 0.943 | 1.060 |
of which corporate and overheads | 1.383 | 1.726 |
Distribution | 0.572 | 0.537 |
Sales, marketing and travel | 0.304 | 0.410 |
R&D and patent expense | 0.499 | 0.358 |
Occupancy | 0.164 | 0.208 |
Finance costs | 0.299 | 0.796 |
Depreciation and amortisation | 0.081 | 0.077 |
Impairment (net) | -0.005 | 0.088 |
Total expenses | 7.844 | 8.667 |
Period revenue (AUD Mn)
| Period revenue (AUD Mn) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
H1 revenue | 1.081 | 1.611 | 1.496 | 1.078 |
H2 revenue (derived) | 0.849 | 1.435 | 1.765 | 2.003 |
FY2026 quarterly revenue (AUD Mn) | Q1 Sep-25 | Q2 Dec-25 | Q3 Mar-26 | Q4 Jun-26 |
Revenue (AUD Mn) | 0.699 | 0.379 | 0.729 | 1.274 |
Cash receipts (AUD Mn) | — | 0.691 | 0.588 | 0.775 |
Balance Sheet and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total assets (AUD Mn) | 4.73 | — | 3.336 | 5.210 |
Cash and equivalents (AUD Mn) | 2.60 | 0.990 | 0.883 | 2.048 |
Trade receivables, net (AUD Mn) | — | — | 0.516 | 1.076 |
R&D tax offset receivable (AUD Mn) | — | — | 0.626 | 0.985 |
Inventories, net (AUD Mn) | — | — | 0.770 | 0.767 |
Borrowings – current (AUD Mn) | — | — | 0 | 12.344 |
Borrowings – non-current (AUD Mn) | 0.05 | 0.86 | 5.333 | 0 |
Lease liabilities (AUD Mn) | — | — | 0.125 | 0.073 |
Net debt incl. leases (AUD Mn, derived) | — | — | 4.576 | 10.369 |
Total equity (AUD Mn) | — | -0.028 | -4.116 | -9.218 |
Goodwill and intangibles (AUD Mn) | — | — | 0.004 | 0.003 |
Working capital (AUD Mn, derived) | 2.80 | — | 1.122 | -9.274 |
NTA per share (A$ cents) | — | — | -1.72 | -3.77 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | — | — | 3.124 | 2.646 |
Operating cash flow (AUD Mn) | -6.107 | -2.583 | -1.985 | -4.279 | -5.029 |
Capex (AUD Mn) | — | — | — | -0.010 | -0.011 |
Free cash flow (AUD Mn, derived) | — | — | — | -4.290 | -5.040 |
Related-party loans received (AUD Mn) | — | — | — | 4.239 | 6.283 |
Equity issued (AUD Mn) | — | — | — | 0 | 0.006 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%) | n/m | n/m |
ROA (%, loss / average assets) | — | -121.0 |
ROIC (%) | n/m | n/m |
Current ratio (x) | 1.55 | 0.36 |
Debt / equity (x) | n/m | n/m |
Net debt / EBITDA (x) | n/m | n/m |
Interest coverage, EBIT / finance costs (x) | -14.4 | -6.0 |
Asset turnover (x, revenue / average assets) | — | 0.72 |
Receivable days, trade only | 62 | 132 |
Inventory days | 177 | 193 |
Payable days | 215 | 211 |
Cash conversion cycle (days) | 24 | 114 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia (AUD Mn) | 2.949 | 2.750 |
International (AUD Mn) | 0.082 | 0.220 |
Region YoY growth (%)
| Region YoY growth (%) | FY2026 |
|---|---|
Australia (%) | -6.7 |
International (%) | 168.7 |
Revenue by Region
| Category (AUD Mn) | FY2025 | FY2026 |
|---|---|---|
Australia – point in time | 1.736 | 2.453 |
Australia – over time (services) | 1.212 | 0.298 |
International – point in time | 0.082 | 0.220 |
Margin Analysis (%) — Share price change, financial year
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price change, financial year (%) | -68.00 | -47.92 | 148.00 | -40.00 | -11.00 |
Valuation Multiples
| Multiple | Aeris | Comment |
|---|---|---|
Market cap | ~A$7.4M | ~247M shares |
Enterprise value | ~A$17.8M | Market cap + A$12.42M debt and leases − A$2.05M cash |
EV / Sales (FY2026) | ~5.8x | — |
EV / EBITDA | n/m | Negative EBITDA |
P/E | n/m | Loss-making |
P/B | n/m | Negative book value |
Debt Facilities
| Facility | Amount (AUD) | Rate | Maturity |
|---|---|---|---|
Director and shareholder loans | 11,152,904 | 10% fixed | Classified current (due within 12 months); extension intended |
Cognian (JV partner) loans | 1,191,000 | Nil | Classified current |
Lease liabilities | 73,056 | Market rate | 34.6k current, 38.4k non-current |
Analyst Conclusions
Management guidance. No quantitative guidance has been given. AR26 sets out FY2027 priorities:
-
grow Syncromesh Prime installations and enterprise opportunities into larger, repeatable revenue streams;
-
scale Syncromesh Omni orders through electrical wholesalers;
-
increase repeat corrosion-protection orders;
-
convert the China portfolio into stable recurring revenue;
-
keep gross margin attractive while controlling expenditure.
The going-concern note refers to an internal budget expecting material sales growth from new products.
Consensus. No sell-side coverage exists.
Bull case:
-
Revenue inflection is visible in the quarterly data. Quarterly revenue rose from A$0.38M (Dec-25) to A$1.27M (Jun-26), and H2 FY2026 revenue was up about 13% on the prior year. This came from repeat OEM corrosion orders and Budweiser expansion, which are more durable than weather-driven services.
-
Omni wholesale gives operating leverage. With gross margin above 50% and largely fixed opex of about A$7M, each additional A$1M of revenue drops roughly A$0.5M toward breakeven. A wholesale channel can scale without proportional cost.
-
Strategic optionality. Blue-chip validation (an Australian bank, the AT&T-linked deployment, Budweiser APAC, Yanjing, a UK integrator) makes Syncromesh or the chemicals IP an attractive tuck-in for a larger player. A$13.35M of unrecognised tax assets add value for an acquirer.
Bear case:
-
The balance sheet is the binding constraint. Net liabilities are A$9.2M, A$12.3M of 10% debt is current, and the going-concern uncertainty is explicit. Any equity raise at about A$0.03 against a A$7M market cap would be heavily dilutive, or the company would sink further into insider debt.
-
There is no track record of sustained growth. Revenue has stayed at A$1.9–3.3M for five years, and FY2026 revenue fell 5.5% despite the "largest" investment year. The cost base is about 2.3 times revenue.
-
Governance and concentration risk. The controlling holders are also lenders and related-party suppliers, and one customer generates 37% of revenue. Outside shareholders' interests could diverge from those of the lender-shareholders in any restructuring.
Key catalysts and monitorables (next 12 months):
-
Outcome of the loan-extension negotiations, which would shift borrowings back to non-current.
-
Any capital raising: its size, price and participants.
-
September 2026 quarterly 4C (due end of October 2026): Omni orders, cash receipts and run-rate.
-
Number of Omni wholesale listings and orders; conversion of the UK and US pipelines.
-
Further UAE OEM orders (expected in H1 FY2027) and volume from the US coil manufacturer.
-
Budweiser and Yanjing order volumes; margins from China manufacturing.
-
2026 AGM resolutions and any exercise of the option over Cognian's 40% of AerisTech.
-
H1 FY2027 results (due February 2027), including the auditor's going-concern wording.
Analyst verdict. Aeris Environmental is a 26-year-old micro-cap trying to rebuild after a pandemic boom that briefly took revenue to A$14.6M and then unwound. The company has made a credible strategic choice. It has coupled its specialty HVAC chemicals franchise, where it holds genuine technical credentials (ASTM B117 corrosion data at more than five years, ARTG disinfectant claims, two-year Budweiser accreditation), with an IoT building-intelligence platform whose camera-free occupancy sensing and wireless retrofit design address real regulatory and energy-cost drivers. Commercial proof points are accumulating, and the June 2026 quarter's A$1.27M of revenue suggests the order book is converting.
The financial position, however, overrides the operating narrative. At 30 June 2026, Aeris had A$2.05M of cash against A$14.4M of liabilities. Nearly all of those liabilities are current related-party loans compounding at 10%. Equity is -A$9.2M and annual operating cash burn is about A$5M. The audited accounts carry a going-concern material uncertainty, and the company's survival currently depends on the continued goodwill of its Chairman, a fellow founding director and a related substantial shareholder. The market's roughly A$7M valuation reflects that dependence. The most likely path forward is a recapitalisation: a debt-to-equity conversion, a rights issue, or both. Existing minority holders face significant dilution in that scenario, even if the business itself progresses.
For an institutional reader, AEI is uninvestable on liquidity and governance grounds and is best treated as a watch-list special situation. The thesis would become actionable only on three observable conditions:
-
a recapitalisation that removes the near-term refinancing overhang on transparent terms;
-
two or more consecutive quarters of revenue above A$1M with cash receipts tracking revenue;
-
quantified Syncromesh Omni wholesale volumes demonstrating channel pull-through.
Until then, the risk-reward favours caution despite the encouraging commercial momentum.
Sources consulted
-
Aeris Environmental Ltd, FY2026 Annual Financial Report and Appendix 4E (28 Aug 2026), via ASX / Webull bulletin mirror
-
Aeris Environmental Ltd, FY2025 Annual Report (29 Aug 2025), ASX
-
Half Year Reports for H1 FY2024 (23 Feb 2024), H1 FY2025 (27 Feb 2025) and H1 FY2026 (27 Feb 2026), ASX
-
Quarterly Activities Reports and Appendix 4C for Jan 2026, Apr 2026 and Jul 2026, ASX / Webull / InvestorPA mirrors
-
Reuters brief, AerisTech JV with Cognian (20 Sep 2024)
-
Aggregators: TipRanks, InvestSMART/Morningstar, Market Index, Simply Wall St, Stoxray, FNArena, Kalkine Media, Morningstar AU, Eulerpool
-
Trade press: Small Caps, HVAC&R News, Appliance Retailer, LabOnline, Australian Made licensee pages
-
Aeris product sheets on aeris.com.au
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Appointed | Background | FY2026 total remuneration (AUD) |
|---|---|---|---|---|
Andrew Just | Chief Executive Officer | 28 Mar 2022 | B.Ec, H.Ec, MBA, GAICD. Former Regional Director Asia Pacific of Radiometer (a Danaher company); about 30 years with GE Healthcare, Danaher, Stryker and Cochlear. NED of Singular Health Group (ASX:SHG) since Mar 2021 and Archer Materials (ASX:AXE) since Dec 2025 | 335,700 (salary 305,700 + super 30,000) |
Robert J. Waring | Company Secretary | 25 Jul 2002 | B.Ec, CA, FCIS, FFin, FAICD; 50+ years in finance and corporate roles; director of Oakhill Hamilton Pty Ltd; also Company Secretary of Vectus Biosystems (ASX:VBS) | Not disclosed separately (not KMP) |
Board of Directors
| Name | Role | Since | Independence (analyst view) | Background |
|---|---|---|---|---|
Maurie Stang | Non-Executive Chairman | 24 Jul 2002 | Not independent: major shareholder, lender and related-party counterparty | 40+ years building healthcare and biotech companies; Executive Chairman of Lumitron Technologies Inc. since 2016; Non-Executive Deputy Chairman of Vectus Biosystems (ASX:VBS) since Dec 2005 |
Steven Kritzler | Non-Executive Director | 24 Jul 2002 | Not independent: major shareholder, lender, related-party counterparty | M.Sc in polymer chemistry (UNSW); holds international patents; Technical Director of Novapharm Research (Australia); 40+ years of commercial R&D |
Dr Abbie Widin | Non-Executive Director | 2 Mar 2021 | Independent | PhD, GAICD; senior roles at Procter & Gamble (Europe/Australia) and Kellogg (APAC); founded an Australian robotics/AI company for the built environment; NED of the Agricultural Business Research Institute |
Dr Jenny Harry | Non-Executive Director | 21 Apr 2021 | Independent | PhD, GAICD, Harvard Business School GMP; co-founder of Proteome Systems; NED of Neuren Pharmaceuticals (ASX:NEU) since Jul 2018 and Genetic Signatures (ASX:GSS) since Oct 2024; NED of Lumitron Technologies Inc. |
Directors' Remuneration
| Name | Fees/salary FY2026 (AUD) | Super (AUD) | Options (AUD) | Total FY2026 (AUD) | Total FY2025 (AUD) |
|---|---|---|---|---|---|
Maurie Stang | 81,081 | 8,919 | 24,128 | 114,128 | 90,000 |
Steven Kritzler | 53,571 | 6,429 | 24,128 | 84,128 | 60,000 |
Abbie Widin | 57,143 | 6,857 | 0 | 64,000 | 64,000 |
Jenny Harry | 64,286 | 7,714 | 0 | 72,000 | 72,000 |
Andrew Just | 305,700 | 30,000 | 0 | 335,700 | 342,293 |
Total KMP | 561,781 | 59,919 | 48,256 | 669,956 | 628,293 |
Major Shareholders
| Holder | Shares | % of ~247M (derived) | Notes |
|---|---|---|---|
Maurie Stang (incl. related entities) | 32,088,487 | ~13.0 | Plus 1,000,000 options; lender of A$4.54M |
Steven Kritzler (incl. related entities) | 21,919,452 | ~8.9 | Plus 1,000,000 options; lender of A$2.23M |
Bernard Stang | — | Substantial holder | Change-in-substantial-holding notice lodged 27 Feb 2026; lender; 1,000,000 options |
Andrew Just (CEO) | 250,000 | ~0.1 | — |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Approx. FY2024 revenue | Relative positioning vs Aeris |
|---|---|---|---|
Siemens Smart Infrastructure (incl. Enlighted IoT) | Building intelligence, lighting/occupancy IoT | ~€21bn (segment) | Dominant BMS and IoT incumbent; Aeris differentiates on wireless retrofit and low cost |
Johnson Controls (OpenBlue) | Building automation | ~US$23bn | Enterprise BMS leader |
Honeywell Building Automation | BMS and sensors | ~US$6–7bn (segment) | Incumbent with strong channels |
Schneider Electric (EcoStruxure Building) | BMS and energy management; electrical wholesale | ~€38bn (group) | Strong in the wholesale channel Omni targets |
Signify (Interact) | Connected lighting control | ~€6bn | Direct overlap in lighting-led IoT |
Ecolab | Industrial hygiene, food and beverage (brewery) sanitation | ~US$15.7bn | Global leader in brewery hygiene; main rival for Budweiser-type accounts |
Diversey (Solenis) | Institutional and food-and-beverage hygiene | Not publicly disclosed post-acquisition | Hygiene incumbent |
Blygold | HVAC coil anti-corrosion coatings | Private; not disclosed | Direct competitor in coil protection |
Heresite Protective Coatings | HVAC coil coatings for OEMs | Private; not disclosed | Direct OEM coil-coating competitor |
Bluefin (US coil coatings) / Electrofin | Coil coatings | Private; not disclosed | Direct competitor in the US |
Nu-Calgon / RectorSeal | HVAC coil cleaners, enzyme cleaners | Private / part of CSW Industrials | Competes on AerisGuard-type products |
Envirosuite (ASX:EVS) | Environmental monitoring software (ASX peer) | ~A$60–70M | Listed ASX environmental-tech comparator |
Peer Comparison FY2026
| Metric | Aeris (FY2026) | Ecolab (FY2024) | Johnson Controls (FY2024) | Siemens SI (FY2024) |
|---|---|---|---|---|
Revenue | A$3.1M | ~US$15.7bn | ~US$23bn | ~€21bn |
Revenue growth | -5.5% | Low single digit | Low single digit | High single digit |
Gross margin | 51–53% | ~43% | ~35% | — |
Operating margin | -156% | ~15–17% | ~10–12% | ~15–17% |
R&D intensity | ~12% (expense line) | ~1–2% | ~2–3% | — |



